Compare MGNX & KVHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGNX | KVHI |
|---|---|---|
| Founded | 2000 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Radio And Television Broadcasting And Communications Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.6M | 177.2M |
| IPO Year | 2013 | 1996 |
| Metric | MGNX | KVHI |
|---|---|---|
| Price | $4.27 | $9.00 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 355.3K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | N/A | ★ 0.03 |
| Revenue | ★ $149,500,000.00 | $9,622,000.00 |
| Revenue This Year | N/A | $28.90 |
| Revenue Next Year | $3.19 | $31.85 |
| P/E Ratio | ★ N/A | $305.00 |
| Revenue Growth | N/A | ★ 3.82 |
| 52 Week Low | $1.30 | $5.09 |
| 52 Week High | $5.08 | $13.00 |
| Indicator | MGNX | KVHI |
|---|---|---|
| Relative Strength Index (RSI) | 46.57 | 46.86 |
| Support Level | $1.49 | $8.78 |
| Resistance Level | $4.55 | $9.79 |
| Average True Range (ATR) | 0.33 | 0.64 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 12.57 | 23.36 |
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
KVH Industries Inc provides integrated, end-to-end services, software, and hardware that support its customers' need for access to the Internet, VoIP, operations content, and entertainment services. It offers high-speed Internet and Voice over Internet Protocol (VoIP) services via satellite and integrated 5G/LTE cellular communications to mobile users at sea and on land. The company also provides commercially licensed entertainment, including news, sports, music, and movies, to commercial and leisure customers in the maritime, hotel, and retail markets. It operates in several geographic areas, including internationally. Revenues are generated from international locations, mainly consisting of Singapore, Canada, South America, European Union and other European countries, and other regions.